June 26, 2013
1 min read

Anti-VEGF for polypoidal choroidal vasculopathy improves visual acuity up to 2 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Three ranibizumab injections and subsequent re-injections improved visual acuity and foveal thickness but did not eliminate branching vascular networks in eyes with polypoidal choroidal vasculopathy, according to a study. Improvements in visual acuity decreased after 1 year.

The prospective study included 75 eyes of 73 patients with symptomatic polypoidal choroidal vasculopathy who received one monthly intravitreal 0.5 mg injection of Lucentis (ranibizumab, Genentech) for 3 months and subsequent re-injection on an as-needed basis. Two-year results were analyzed.

LogMAR visual acuity improved from 0.59 at baseline to 0.37 at 1 year and 0.41 at 2 years after the first injection; both improvements were statistically significant (P = .001). However, visual acuity diminished slightly in the second year. Improvements in foveal thickness persisted in the second year.

Polypoidal lesions were absent from 30 eyes (40%) 1 year after the first injection and 19 eyes (25%) at 2 years.

All eyes had branching vascular networks 2 years after the initial injection; networks increased in size in the second year.